Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors
Author: ["G. Haase","P. Kennel","B. Pettmann","E. Vigne","S. Akli","F. Revah","H. Schmalbruch","A. Kahn"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy cause progressive paralysis, often leading to premature death. Neurotrophic factors have been suggested as therapeutic agents for motor neuron diseases, but their clinical use as injected recombinant protein was limited by toxicity and/or poor bioavaiiability. We demonstrate here that adenovirus-mediated gene transfer of neurotrophin-3 (NT-3) can produce substantial therapeutic effects in the mouse mutant pmn (progressive motor neuronopathy). After intramuscular injection of the NT-3 adenoviral vector, pmn mice showed a 50% increase in life span, reduced loss of motor axons and improved neuromuscular function as assessed by electromyography. These results were further improved by coinjecting an adenoviral vector coding for ciliary neurotrophic factor. Therefore, adenovirus-mediated gene transfer of neurotrophic factors offers new prospects for the treatment of motor neuron diseases.
Cite this article
Haase, G., Kennel, P., Pettmann, B. et al. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med 3, 429–436 (1997). https://doi.org/10.1038/nm0497-429
